MACC1 INVOLVED IN THE REGULATION OF RESISTANCE OF HUMAN EPIDERMAL GROWTH FACTOR RECEPTOR 2-POSITIVE GASTRIC CANCER CELLS TO TRASTUZUMAB

被引:0
|
作者
Zhang, Guofei [1 ]
Hu, Kefu [1 ]
Yu, Rong [1 ]
Su, Gang [1 ]
Xiong, Xin [1 ]
Hu, Daqian [1 ]
Zhang, Zhihong [1 ]
机构
[1] Gongan Cty Peoples Hosp, Dept Oncol, Shizikou Town, Gongan County, Peoples R China
来源
ACTA MEDICA MEDITERRANEA | 2019年 / 35卷 / 05期
关键词
MACC1; gene; human HER2-positive gastric cells; trastuzumab; resistance; POOR-PROGNOSIS; EXPRESSION; LONG;
D O I
10.19193/0393-6384_2019_5_381
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Objective: We sought to analyze whether the mechanism of the MACC1 gene involved in human epidermal growth factor receptor 2 (HER2)-positive gastric cancer cells regulates trastuzumab-resistant gastric cancer. Methods: Cell lines sensitive to trastuzumab and positive for MACC1 and HER2 expression were screened from human gastric cancer cell lines, drug-resistant cell MKN45/TR was established by a stepwise dose-increase method, and the expression level o f MACC1 protein in trastuzumab-resistant cells was detected using Western blot. The inhibition rate of cell proliferation after trastuzumab treatment for 72 hours was detected using MTT. Results: Drug-resistant cell MKN45/TR was established using a stepwise dose-increase method. Half-maximal inhibitory concentration and resistance index of cell trastuzumab were detected during the induction period .The induction time was five months and the final induction concentration was 2,500 mu g/mL. Additionally, the half-maximal inhibitory concentration of trastuzumab was 295.15 mu g/mL and the drug resistance index was 9.67. Western blot detection results showed that, as compared with cells without drug resistance, the MACC1 protein level of trastuzumab-resistant cells obviously increased. NCI-N87/TR and MKN45/TR were given transinfection using MACC1 interference and empty vector and were treated using different concentrations of trastuzumab. The cell inhibition rate was detected using the MTT method. Under the function of trastuzumab at concentrations of 20 mu g/mL, 80 mu g/mL, and 160 mu g/mL, there was statistical significance between the interference group and the control group with respect to the inhibition rate of cell proliferation (P<0.05). Conclusion: MACC1 participates in the regulation of trastuzumab in gastric cancer cells. The expression level of MACC1 protein cells in transinfection resistance increases, thus interfering MACC1 in resistance cells and reversing the resistance of MACC1.
引用
收藏
页码:2439 / 2443
页数:5
相关论文
共 50 条
  • [41] Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer and Central Nervous System Metastases
    Leyland-Jones, Brian
    JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (31) : 5278 - 5286
  • [42] Feasibility and pharmacokinetics of combined therapy with S-1 and trastuzumab in patients with human epidermal growth factor receptor 2-positive metastatic or recurrent breast cancer
    Yasuhiro Suzuki
    Rin Ogiya
    Risa Oshitanai
    Mayako Terao
    Mizuho Terada
    Toru Morioka
    Banri Tsuda
    Naoki Niikura
    Takuho Okamura
    Yuki Saito
    Yutaka Tokuda
    International Journal of Clinical Oncology, 2014, 19 : 274 - 279
  • [43] Phase II Trial of Pertuzumab and Trastuzumab in Patients With Human Epidermal Growth Factor Receptor 2-Positive Metastatic Breast Cancer That Progressed During Prior Trastuzumab Therapy
    Baselga, Jose
    Gelmon, Karen A.
    Verma, Shailendra
    Wardley, Andrew
    Conte, PierFranco
    Miles, David
    Bianchi, Giulia
    Cortes, Javier
    McNally, Virginia A.
    Ross, Graham A.
    Fumoleau, Pierre
    Gianni, Luca
    JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (07) : 1138 - 1144
  • [44] Synergistic anticancer effects of ruxolitinib and calcitriol in estrogen receptor-positive, human epidermal growth factor receptor 2-positive breast cancer cells
    Lim, Seung Taek
    Jeon, Ye Won
    Gwak, Hongki
    Kim, Se Young
    Suh, Young Jin
    MOLECULAR MEDICINE REPORTS, 2018, 17 (04) : 5581 - 5588
  • [45] Antibody-nanoparticle conjugate constructed with trastuzumab and nanoparticle albumin-bound paclitaxel for targeted therapy of human epidermal growth factor receptor 2-positive gastric cancer
    Xiong, Jian
    Han, Shuhua
    Ding, Shuang
    He, Jingchao
    Zhang, Haijun
    ONCOLOGY REPORTS, 2018, 39 (03) : 1396 - 1404
  • [46] Time to first tumor progression as a predictor of efficacy of continued treatment with trastuzumab beyond progression in human epidermal growth factor receptor 2-positive metastatic breast cancer
    Hayashi, Mitsuhiro
    Okumura, Yasuhiro
    Osako, Tomofumi
    Toyozumi, Yasuo
    Arima, Nobuyuki
    Iwase, Hirotaka
    Nishimura, Reiki
    INTERNATIONAL JOURNAL OF CLINICAL ONCOLOGY, 2011, 16 (06) : 694 - 700
  • [47] Strategy for treatment of stage IV human epidermal growth factor 2-positive gastric cancer: a case report
    Sakaguchi, Masazumi
    Shimoike, Norihiro
    Akagawa, Shin
    Kanaya, Seiichiro
    JOURNAL OF MEDICAL CASE REPORTS, 2019, 13 (01)
  • [48] Inetetamab combined with S-1 and oxaliplatin as first-line treatment for human epidermal growth factor receptor 2-positive gastric cancer
    Kong, Ying
    Dong, Qi
    Jin, Peng
    Li, Ming-Yan
    Ma, Li
    Yi, Qi-Jun
    Miao, Yu-E
    Liu, Hai-Yan
    Liu, Jian-Gang
    WORLD JOURNAL OF GASTROENTEROLOGY, 2024, 30 (40) : 4367 - 4375
  • [49] Adding hormonal therapy to chemotherapy and trastuzumab improves prognosis in patients with hormone receptor-positive and human epidermal growth factor receptor 2-positive primary breast cancer
    Hayashi, Naoki
    Niikura, Naoki
    Yamauchi, Hideko
    Nakamura, Seigo
    Ueno, Naoto T.
    BREAST CANCER RESEARCH AND TREATMENT, 2013, 137 (02) : 523 - 531
  • [50] Hormone Receptor/Human Epidermal Growth Factor Receptor 2-positive breast cancer: Where we are now and where we are going
    Schettini, Francesco
    Buono, Giuseppe
    Cardalesi, Cinzia
    Desideri, Isacco
    De Placido, Sabino
    Del Mastro, Lucia
    CANCER TREATMENT REVIEWS, 2016, 46 : 20 - 26